Profile picture

Doctor Kunal Mahajan

Himachal Heart Institute, Mandi (India)
Membership: FESC Member
Follow
Biography
Dr. Kunal Mahajan, MD DM FACC FESC FSCAI FAPSC FAPSIC FISH FISC currently works as Chief of Interventional Cardiology in the Himachal Heart Institute, Mandi India. He has a keen interest in Interventional Cardiology as well as preventive cardiology and has more than 100 indexed publications to his credit. He has participated as faculty in various national/international conferences.
Logo ESC

Contributor content

Beyond the stent: routine vascular ultrasound after PCI reveals polyvascular extreme risk without intensified LDL‑cholesterol lowering therapy
Presentation
Beyond the stent: routine vascular ultrasound after PCI reveals polyvascular extreme risk without intensified LDL‑cholesterol lowering therapy
One- versus three-month dual antiplatelet therapy in high-bleeding-risk patients undergoing PCI: a bayesian and trial sequential meta-analysis
Presentation
One- versus three-month dual antiplatelet therapy in high-bleeding-risk patients undergoing PCI: a bayesian and trial sequential meta-analysis
Apolipoprotein C-III inhibition reduces acute pancreatitis in familial chylomicronemia syndrome: a meta-analysis of randomized trials
Presentation
Apolipoprotein C-III inhibition reduces acute pancreatitis in familial chylomicronemia syndrome: a meta-analysis of randomized trials
Sustained combination lipid-lowering therapy determines durability of LDL-C <55 mg/dL after ACS: a structured implementation study (2022–2026)
Presentation
Sustained combination lipid-lowering therapy determines durability of LDL-C <55 mg/dL after ACS: a structured implementation study (2022–2026)
Is restrictive transfusion too restrictive in acute coronary syndromes with anemia? A meta-analysis of early and mid-term randomized outcomes
Presentation
Is restrictive transfusion too restrictive in acute coronary syndromes with anemia? A meta-analysis of early and mid-term randomized outcomes
Transient surge, persistent risk: longitudinal changes in lipoprotein(a) following acute coronary syndrome
Presentation
Transient surge, persistent risk: longitudinal changes in lipoprotein(a) following acute coronary syndrome
LDL-C target achievement does not equal risk resolution after ACS: residual atherogenic and inflammatory burden despite maximal oral triple lipid therapy
Presentation
LDL-C target achievement does not equal risk resolution after ACS: residual atherogenic and inflammatory burden despite maximal oral triple lipid therapy
Impact of elevated lipoprotein(a) on LDL-C lowering efficacy in ACS patients undergoing triple lipid-lowering therapy: insights from LAI-REACT-LP(a) sub-study
Presentation
Impact of elevated lipoprotein(a) on LDL-C lowering efficacy in ACS patients undergoing triple lipid-lowering therapy: insights from LAI-REACT-LP(a) sub-study
Suboptimal LDL-C control despite high statin use: insights from the LAI-LCARE survey on secondary CAD prevention in India
Presentation
Suboptimal LDL-C control despite high statin use: insights from the LAI-LCARE survey on secondary CAD prevention in India
Efficacy of combination lipid lowering therapy in achieving low density lipoprotein cholesterol targets after one month of event in patients with acute coronary syndrome
Presentation
Efficacy of combination lipid lowering therapy in achieving low density lipoprotein cholesterol targets after one month of event in patients with acute coronary syndrome